Efficacy of refractory non small cell lung cancer Patients treated with taxel and cisplatin

In order to search the effectiveness of Taxel+Cisplatin in patients with non small cell lung cancer (NSCLC),from May 1995 to November 1997,21 cases of NSCLC patients were treated with the combination regimen of taxel and cisplatin.All patients were resistant to several kinds of chemotherapeutic protocols such as CAP,EP,NVB P or VDS P.After two courses of treatment,their efficiency and toxicity were evaluated according to the WHO's criteria,the ovreall response rate(CR+PR)was 35 0%(7/20)with no CR and seven PR.The major toxicity were descent WBC and platelet counts,diarrhea,myalgia/arthralgia.However,Ⅲ Ⅳ grade of neutropenia and thrombocytopenia were rare observed,and most of them were tolerable.We think this protocol is safe and effective for resistant NSCLC patients.